Top

Global HER-2 Positive Breast Cancer Market 2015-2019

Category : Healthcare  | Published Date : March-2015 | Pages : 123
enquire GET DISCOUNT
About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 
percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients. 

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas 
• APAC
• EMEA        

Key Vendors
• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

Other Prominent Vendors
 • Actavis
• Array BioPharma
• Biocad
• Biocon
• Boehringer Ingelheim
• Bristol-Myers Squibb 
• Celltrion
• Chugai Pharmaceutical
• DARA BioSciences
• EddingPharm 
• Eisai 
• Galena Biopharma
• Halozyme Therapeutics
• Hospira 
• Mylan 
• Oncothyreon
• Pfizer 
• ProStrakan
• Puma Biotechnology
• Sun Pharmaceutical Industries 
• Synta Pharmaceuticals
• Teva Pharmaceutical 

Market Driver
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report

Market Challenge
• Poor Diagnosis and Screening
• For a full, detailed list, view our report

Market Trend
• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 Immunohistochemistry
06.4.2 FISH
06.4.3 SPoT-Light HER2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden
07. Pipeline Analysis
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 HER-2 Positive Breast Cancer Market in US
08.3.1 Market Size and Forecast
08.4 HER-2 Positive Breast Cancer Market in EU
08.4.1 Market Size and Forecast
08.5 Five Forces Analysis
09. Market Segmentation by Type of Therapy
09.1 Chemotherapy
09.1.1 Alkylating agents
09.1.2 Antimetabolites
09.1.3 Cytotoxic antibiotics
09.1.4 Taxanes
09.2 Targeted Therapy
09.3 Hormone Therapy
10. Market Segmentation by Molecule Type
10.1 Biologics
10.2 Small Molecules
11. Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Competitive Assessment of the Top Drugs
20.2.2 Celgene
20.2.3 F. Hoffmann-La Roche
20.2.4 GlaxoSmithKline
20.2.5 Novartis
20.2.6 Sanofi
20.3 SWOT Analysis of the Targeted Therapies
20.3.1 Herceptin
20.3.2 Kadcyla
20.3.3 Perjeta
20.3.4 Tykerb
20.4 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Celgene
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Strategy
21.1.4 Business Segmentation by Revenue
21.1.5 Sales by Geography
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Novartis
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Sanofi
21.5.1 Key Facts
21.5.2 Business Description
21.5.3 Business Segmentation
21.5.4 Revenue by Business Segmentation
21.5.5 Revenue Comparison 2012 and 2013
21.5.6 Sales by Geography
21.5.7 Business Strategy
21.5.8 Key Developments
21.5.9 SWOT Analysis
22. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global HER-2 Positive Breast Cancer Market 2015-2019
Exhibit 3: Pathophysiology: HER-2 Positive Breast Cancer
Exhibit 4: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014
Exhibit 5: Diagnosis of HER-2 Positive Breast Cancer: IHC
Exhibit 6: Diagnosis of HER-2 Positive Breast Cancer: FISH
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines: HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of the HER-2 Positive Breast Cancer Market in US
Exhibit 10: Pipeline Snapshot: Combination Therapies
Exhibit 11: Pipeline Snapshot: Therapeutic Vaccines
Exhibit 12: Snapshot of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 13: Global HER-2 Positive Breast Cancer Market 2014-2019 (US$ million)
Exhibit 14: Drivers and Challenges of the Global HER-2 Positive Breast Cancer Market
Exhibit 15: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 16: HER-2 Positive Breast Cancer Market in EU 2014-2019 (US$ million)
Exhibit 17: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy
Exhibit 18: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy 2014
Exhibit 19: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type
Exhibit 20: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type 2014
Exhibit 21: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration
Exhibit 22: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration 2014
Exhibit 23: Geographical Segmentation of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 24: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
Exhibit 25: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer in 2013 (US$ million)
Exhibit 26: Product Portfolio: Celgene
Exhibit 27: YoY Growth Rate and Global Revenue of Abraxane 2010-2013 (US$ million)
Exhibit 28: Product Portfolio: F. Hoffmann-La Roche
Exhibit 29: YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million)
Exhibit 30: Revenue of Perjeta for 2012-2013 (US$ million)
Exhibit 31: YoY Growth Rate and Revenue of Xeloda 2010-2013 (US$ million)
Exhibit 32: Product Portfolio: GlaxoSmithKline
Exhibit 33: YoY Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
Exhibit 34: Product Portfolio: Novartis
Exhibit 35: YoY Growth Rate and Revenue of Femara 2010-2013 (US$ million)
Exhibit 36: Product Portfolio: Sanofi
Exhibit 37: YoY Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million)
Exhibit 38: Herceptin: SWOT Analysis
Exhibit 39: Kadcyla: SWOT Analysis
Exhibit 40: Perjeta: SWOT Analysis
Exhibit 41: Tykerb: SWOT Analysis
Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 43: Celgene: Sales by Geography 2013
Exhibit 44: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 45: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 47: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 48: GlaxoSmithKline: Business Segmentation 2013
Exhibit 49: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 50: GlaxoSmithKline: Sales by Geography 2013
Exhibit 51: GlaxoSmithKline: Pipeline Products 2013
Exhibit 52: Novartis AG: Business Segmentation
Exhibit 53: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 54: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 55: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 56: Sanofi SA: Business Segmentation
Exhibit 57: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 58: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 59: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 3000
Five User: US $ 3500
Site User: US $ 4500
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top